EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
NCT02664363
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
3
Enrollment
OTHER
Sponsor class
Stopped
Study funding ended
Conditions
Glioblastoma
Gliosarcoma
Interventions
BIOLOGICAL:
EGFRvIII CAR T cells
Sponsor
Daniel Landi